You can buy or sell Intersect ENT and other stocks, options, ETFs, and crypto commission-free!
Intersect ENT, Inc. Common Stock, also called Intersect ENT, is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Read More The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.
Menlo Park, California
52 Week High
52 Week Low
Yahoo FinanceMay 14
Steven Cohen Dives Deeper Into Intersect ENT
- By Sydnee Gatewood Billionaire investor Steven Cohen (Trades, Portfolio), who leads Point72 Asset Management, disclosed on May 10 that he expanded his stake in Intersect ENT Inc. (XENT) by 221.55%. The guru's Connecticut-based hedge fund seeks to generate superior risk-adjusted returns using long, short, macro and systematic strategies. According to GuruFocus Real-Time Picks, a Premium feature, Cohen invested in 1.16 million shares of the California-based medical devices manufacturer on May 9. ...
Yahoo FinanceMay 13
Abiomed and Intersect ENT Stumble to Start 2019
Med-tech stocks like Abiomed (NASDAQ: ABMD) and Intersect ENT (NASDAQ: XENT) have been red hot in recent years. However, both of these businesses recently failed to live up to investors' expectations. In this episode of The Motley Fool's Industry Focus: Healthcare, host Shannon Jones and Fool.com contributor Brian Feroldi discuss what went wrong for both of these companies and whether the businesses can recover. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. A...
Yahoo FinanceMay 8
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Intersect ENT, Inc. Investors (XENT)
BENSALEM, Pa.--(BUSINESS WIRE)-- Law Offices of Howard G. Smith announces an investigation on behalf of Intersect ENT, Inc. (“Intersect ENT” or the “Company”) (NASDAQ: XENT) investors concerning the Company and its officers’ possible violations of federal securities laws. On May 6, 2019, the Company disclosed a first quarter loss of $10.8 million, as well as a lowered guidance for the remainder of 2019. In addition to this news, the Company also reported that its CEO of 11 years will be stepping down on J...
-$0.30 per share
-$0.35 per share